Search Results

You are looking at 1 - 10 of 117 items for :

  • "racial disparities" x
  • Refine by Access: All x
Clear All
Full access

Presenters: Shonta Chambers, Elizabeth Harrington, Lisa A. Lacasse, Robert Winn, and moderated by Alyssa A. Schatz

, research also shows dramatic racial disparities in access to guideline-adherent cancer care—particularly between Black and White patients—although significant cancer disparities also exist in the delivery of care to indigenous and Hispanic communities. 7

Full access

Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh

.9% to 77.7% ( P <.001), and 55.9% to 50.0% ( P <.001) at 12 months, 3 months, and 1 month, respectively, before death. Discussion There is sufficient evidence from prior investigations to support the existence of racial disparities in care among

Full access

Norma F. Kanarek, Hua-Ling Tsai, Sharon Metzger-Gaud, Dorothy Damron, Alla Guseynova, Justin F. Klamerus, and Charles M. Rudin

of use of primary care services. 21 In the case of therapeutic trials, racial disparities were observed in the catchment area, with African Americans in the catchment area outside Baltimore City participating less than white persons. This finding may

Full access

Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju

guideline-concordant treatment. Racial disparities in receipt of guideline-concordant care have been well described. Black women are less likely to receive care that is concordant with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for

Full access

Krista Michelle Wong, Seshma Ramsawak, and Hasan Abuamsha

racial disparity in appendiceal cancer-specific survival exists among appendiceal cancer SEER patients. Further research is needed to address the underlying cause of these disparities in order to improve outcomes. Table: Bivariable and multivariable

Full access

Adam C. Powell, Christopher T Lugo, Jeremy T Pickerell, James W Long, Bryan A Loy, and Amin J Mirhadi

.05). Conclusions : In the homogeneously insured population examined, both unadjusted and adjusted analyses provided no evidence of a Black / White racial disparity in access to lung surgery for Stage 1 lung cancer, or in timeliness of access. HSR22-161 Table

Full access

Malak Abuamsha, Hasan Abuamsha, and Raed Bahelah

. Significant racial disparity in the incidence rate and outcomes has been documented in the literature. However, there has been limited data on the racial disparity in young women's breast cancer survival. We, therefore, sought to examine the differences in

Full access

Surbhi Agarwal, Ruta Rao, and David Ansell

Background: NCCN quality measures for breast cancer include (1) radiation therapy administered within 1 year of diagnosis for women under age 70 receiving breast-conserving surgery; (2) chemotherapy considered in 4 months of diagnosis for women under 70 with T1c or stage II/III ER/PR- tumors; (3) endocrine therapy administered within 1 year of diagnosis for women with AJCC T1 or stage II/III ER/PR+ breast cancer. These evidence-based measures promote accountability for providers and allow transparency in quality of care. Black women are less likely than white women to receive these therapies that are associated with a survival benefit. Improving adherence to guidelines can decrease the gap in mortality rates for minority women with breast cancer. Methods: We performed a retrospective chart review on patients with breast cancer between April 2010 and October 2015 at Rush University. Information collected included time of diagnosis, clinical stage, ER/PR status, surgical procedures, radiation, chemotherapy, endocrine therapy, and demographics. Chi-squared analysis was done to compare percent of black versus white women who met each quality guideline. Results: In total, 2,436 women were analyzed, of whom 30.3% were black, 66% were white, and 3.7% were other. Of this cohort, 779 women met inclusion criteria for quality guideline 1, and there was no significant difference between black and white women who did not receive radiation therapy (P=.21; 24.7% vs 20.4%). For quality guideline 2 (n=382), there was also no significant difference between black and white women who did not get chemotherapy within 4 months of diagnosis (P=.32; 36.6% vs 31.4%). However, for quality guideline 3 (n=1,222), there was a statistically significant difference between black and white women who did not get hormone therapy within a year of diagnosis (P=.0008; 36.9% vs 26.1%). Conclusions: Endocrine therapy reduces risk of recurrence and mortality in women with ER/PR positive breast cancer; however, there is a disparity between black versus white women who meet this NCCN quality measure. Further studies are needed to understand the reason for this gap in quality of care so that specific interventions can be implemented to eliminate this disparity.

Full access

Shannon Ugarte, Annie Tang, Zhonet Harper, Rohan E. John, Kala Mehta, Amal Khoury, and Kevin Knopf

Full access

Lindsay J. Collin, Ming Yan, Renjian Jiang, Keerthi Gogineni, Preeti Subhedar, Kevin C. Ward, Jeffrey M. Switchenko, Joseph Lipscomb, Jasmine Miller-Kleinhenz, Mylin A. Torres, Jolinta Lin, and Lauren E. McCullough

Background In the United States, racial disparities in breast cancer outcomes are well-documented, with non-Hispanic Black (NHB) women more likely to die of their disease than their non-Hispanic White (NHW) counterparts. 1 – 3 The disparity is